Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 4 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 4Colorectal Neoplasms 4Rectal Neoplasms 3Diarrhea 3Carcinoid Tumor 3Gastro-enteropancreatic neuroendocrine tumor 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Malignant Carcinoid Syndrome 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma 1Breast Neoplasms 1Anus Neoplasms 1Adenoma, Islet Cell 1

Interventions

Octreotide 3lanreotide 2Everolimus 2pasireotide 1Sunitinib 1Serotonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoid Tumor × Octreotide × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00412061 2014-11-21

RADIANT-2

Novartis

Phase 3 Completed
429 enrolled 13 charts
Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT00690430 2013-07-30

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Novartis

Phase 3 Completed
186 enrolled 11 charts
Endocrine

Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡